A new form of chemo-immunotherapy combination works very well — in mice!

Alas, our friends at The Daily Telegraph in the UK seem to have managed to hyperinflate some early scientific findings into an overnight cure for prostate cancer in general and  metastatic, castration-resistant prostate cancer in particular. … READ MORE …

The PATCH study will continue to accrue patients in the UK

The Prostate Adenocarcinoma: TransCutaneous Hormones or PATCH trial is an ongoing study in the UK that was designed (in a series of stages) to determine whether estrogen patch therapy might be at least no worse than (i.e., “non-inferior” to) LHRH agonist therapy in suppressing androgens to castrate level. … READ MORE …

New genetic mechanism explains prostate cancer progression in androgen-suppressed patients

According to a media release from Cancer Research UK yesterday, “The first-ever comprehensive study of prostate cancer tissue has revealed a completely new gene network driving the disease in patients who have stopped responding to standard hormone treatment.” … READ MORE …

Degarelix as second-line ADT in men not responsive to LHRH agonist therapy

First-line androgen deprivation therapy (ADT) for a man with metastatic prostate cancer has long been been either surgical or medical castration. In the case of medical castatration, the form of medication most commonly used since the mid to late 1980s has been an LHRH agonist (e.g., leuprolide acetate). … READ MORE …

Acid-suppressive therapy + ketoconazole in men with CRPC

Ketoconazole has long been used as a “third-line” agent in men with castration-resistant prostate cancer (CRPC) who have progressive disease after standard forms of hormonal therapy. For some patients, ketoconazole can be clinically effective and cost-effective compared to other clinical options. … READ MORE …